Neurodegenerative disease management最新文献_第5页

Real-world experience of ozanimod in adults with multiple sclerosis. ozanimod在成人多发性硬化症中的实际应用经验。

IF 2.8

Neurodegenerative disease management Pub Date : 2026-08-01 Epub Date: 2026-01-29 DOI: 10.1080/17582024.2026.2622078

Jessica Cooperrider, Jeffrey Lambe, Michelle Chu, Mengke Du, Jennifer Reardon, Burhan Chaudry, Andrew Thorpe, Carrie M Hersh, Devon Conway

{"title":"Real-world experience of ozanimod in adults with multiple sclerosis.","authors":"Jessica Cooperrider, Jeffrey Lambe, Michelle Chu, Mengke Du, Jennifer Reardon, Burhan Chaudry, Andrew Thorpe, Carrie M Hersh, Devon Conway","doi":"10.1080/17582024.2026.2622078","DOIUrl":"10.1080/17582024.2026.2622078","url":null,"abstract":"Aim: Ozanimod is a second-generation sphingosine 1-phosphate receptor (S1PR) modulator approved for treatment of relapsing multiple sclerosis (MS). Data are lacking for ozanimod use in real-world clinical practice. This study aims to determine characteristics of people with MS (pwMS) prescribed ozanimod as well as ozanimod persistence, tolerability, safety, and effectiveness over one year.Methods: Data were retrospectively collected for adults with MS or clinically isolated syndrome who received ozanimod at two tertiary MS centers.Results: We identified 206 pwMS for inclusion. Many (n = 146, 71%) had prior disease-modifying therapy (DMT) experience. The most common reasons for switching to ozanimod were cost (n = 48, 33%) and prior DMT intolerance (n = 29, 20%). Most individuals (n = 149, 72%) remained on ozanimod at last data collection. The most frequent reason for discontinuation was side effects (n = 21, 37% of discontinuers, 10.2% of total cohort). Few pwMS reported tolerability concerns (7.5% at 12 months). When comparing pre-ozanimod baseline to 12-month data, the annualized relapse rate was reduced by 56% (p = 0.034), and fewer pwMS had new/enlarging brain MRI T2 lesions (6.6% versus 40%, p < 0.001) and gadolinium-enhancing lesions (3.9% versus 27%, p = 0.027).Conclusion: Ozanimod was well-tolerated with good treatment persistence, a favorable safety profile, and reductions in clinical and radiographic disease.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"401-409"},"PeriodicalIF":2.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13390510/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146086372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multivariate analysis of sex differences in Parkinson's disease: the distinct contributions of fall-related self-efficacy and voice handicap. 帕金森病性别差异的多变量分析：跌倒相关自我效能感和声音障碍的显著贡献。

IF 2.8

Neurodegenerative disease management Pub Date : 2026-08-01 Epub Date: 2026-03-16 DOI: 10.1080/17582024.2026.2645615

Halil Onder, Zehra Yavuz, Sevim Kapukaya, Ahmet Gunaydin, Tuba Teksut, Nursu Erdogan, Selcuk Comoglu

{"title":"Multivariate analysis of sex differences in Parkinson's disease: the distinct contributions of fall-related self-efficacy and voice handicap.","authors":"Halil Onder, Zehra Yavuz, Sevim Kapukaya, Ahmet Gunaydin, Tuba Teksut, Nursu Erdogan, Selcuk Comoglu","doi":"10.1080/17582024.2026.2645615","DOIUrl":"10.1080/17582024.2026.2645615","url":null,"abstract":"Background: Sex-related differences in Parkinson's disease (PD) have been frequently reported, yet most studies are descriptive and do not account for confounders. Identifying independent predictors may clarify sex-linked features and guide management.Objectives: To determine independent predictors of sex differences in a well-characterized PD cohort through multivariate analysis encompassing motor and non-motor domains.Methods: A total of 652 PD patients (253 women, 392 men) from a tertiary movement disorders clinic were retrospectively evaluated. Assessments included MDS-UPDRS Parts I - IV, Non-Motor Symptoms Scale (NMSS), Hamilton Anxiety and Depression scales, FES-I, Parkinson's Disease Questionnaire-39, and Voice Handicap Index (VHI). Sex differences were analyzed with univariate tests and multivariate logistic regression.Results: Women had higher MDS-UPDRS Part I, anxiety, and FES-I scores, while men scored higher on VHI and NMSS domains. In multivariate models, higher FES-I independently predicted female sex (OR 0.52), and higher VHI predicted male sex (OR 1.83). No independent differences were found for depression, quality of life, motor subtype, levodopa response, or RBD.Conclusions: Sex differences in PD appear selective rather than global. Fear of falling in women and voice-related disability in men were independently associated with sex in this cohort and should be interpreted descriptively rather than causally.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"435-441"},"PeriodicalIF":2.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13390541/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147468639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of self-efficacy and self-management with multiple sclerosis patients' quality of life: a descriptive-analytical study. 自我效能和自我管理与多发性硬化症患者生活质量的关系：一项描述性分析研究。

IF 2.8

Neurodegenerative disease management Pub Date : 2026-08-01 Epub Date: 2026-06-02 DOI: 10.1080/17582024.2026.2645607

Mahnaz Atapour, Farzaneh Maghaminejad, Shahrzad Ghiyasvandian, Mitra Rahimzadeh

{"title":"Association of self-efficacy and self-management with multiple sclerosis patients' quality of life: a descriptive-analytical study.","authors":"Mahnaz Atapour, Farzaneh Maghaminejad, Shahrzad Ghiyasvandian, Mitra Rahimzadeh","doi":"10.1080/17582024.2026.2645607","DOIUrl":"10.1080/17582024.2026.2645607","url":null,"abstract":"Background: Multiple sclerosis (MS), often leading to a lower quality of life (QoL) for patients compared to those with other chronic diseases. Self-efficacy and self-management play crucial roles in influencing the QoL of MS patients.Objectives: This study aimed to investigate the association of self-efficacy and self-management with MS patients' QoL.Methods: The research entailed a descriptive-analytical study involving 210 MS patients selected through simple random sampling. Data was collected with four questionnaires, demographic information, the MSSMs-R, MSSS, as well as MSQOL-54 scales. The gathered data were analyzed using multiple regression model.Results: The study sample consisted of 150 females (71.4%), with 43.3% having university-level education and 82.58% scoring 1-4 on the EDSS scale. The results indicate that Self-efficacy (Beta = 0.283 and 0.389) is the most significant positive predictor of QoL. Along with Health Maintenance Behavior (Beta = 0.278), it accounts for 34.0% of the variance in mental health and, when combined with social/family support, explains 29.7% of the variance in physical health.Conclusions: The study found a strong association between self-management and self-efficacy and the QoL in patients with MS. Strengthening self-management and self-efficacy skills is recommended to improve the QoL. Furthermore, further research into other factors affecting QoL is suggested.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"427-433"},"PeriodicalIF":2.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13390509/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148143967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Geographic distribution of amyotrophic lateral sclerosis-related genes: a systematic review. 肌萎缩性侧索硬化症相关基因的地理分布：系统综述。

IF 2.8

Neurodegenerative disease management Pub Date : 2026-08-01 Epub Date: 2025-08-29 DOI: 10.1080/17582024.2025.2554382

Beliu García-Parra, Josep M Guiu, Mónica Povedano, Pilar Modamio

{"title":"Geographic distribution of amyotrophic lateral sclerosis-related genes: a systematic review.","authors":"Beliu García-Parra, Josep M Guiu, Mónica Povedano, Pilar Modamio","doi":"10.1080/17582024.2025.2554382","DOIUrl":"10.1080/17582024.2025.2554382","url":null,"abstract":"Introduction: Amyotrophic lateral sclerosis (ALS) is a rare motor neuron disease. There is no effective treatment, but disease-modifying therapies do exist. Objective. To identify the geographical distribution of ALS-related genes.Methods: A systematic review was conducted according to the PRISMA 2020 guidelines in PubMed and Web of Science. Inclusion criteria: patients with ALS, no age or gender restriction, English and Spanish languages, studies published until 31 July 2025.Results: Thirty-eight results were obtained, 32 were selected, 19 articles were assessed for eligibility, and 8 articles were included from databases. Three articles recommended by clinical experts were added, so 11 results were reviewed. This research showed that published articles on the geographic distribution of ALS-related genes are limited, particularly for underrepresented regions such as Africa.Conclusion: The findings demonstrate the need for intensified international research to improve knowledge of the genetic epidemiology of ALS.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"511-517"},"PeriodicalIF":2.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13390506/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144962475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of spinocerebellar ataxia. 脊髓小脑共济失调的治疗。

IF 2.8

Neurodegenerative disease management Pub Date : 2026-08-01 Epub Date: 2026-04-30 DOI: 10.1080/17582024.2026.2665356

Egor Vinokurov, Ksenia Marinina, Ilya Bezprozvanny

{"title":"Management of spinocerebellar ataxia.","authors":"Egor Vinokurov, Ksenia Marinina, Ilya Bezprozvanny","doi":"10.1080/17582024.2026.2665356","DOIUrl":"10.1080/17582024.2026.2665356","url":null,"abstract":"Spinocerebellar ataxias (SCAs) are a group of neurodegenerative diseases characterized by progressive cerebellar dysfunction, which leads to impaired coordination, dysarthria, oculomotor disorders, and subsequently to a marked reduction in quality of life and high disability. In addition to the main motor symptoms, patients often suffer from cerebellar cognitive-affective syndrome, depression, and sleep disturbances. Despite advances in understanding the molecular and genetic underpinnings of SCAs, there are currently no disease-modifying therapies approved by the FDA (U.S. Food and Drug Administration) or EMA (European Medicines Agency), and management remains largely symptomatic, focusing on improving quality of life and functional independence. Recent systematic reviews and clinical guidelines emphasize a combination of pharmacological, non-pharmacological, and novel gene and cell therapies that are currently under investigation, with varying levels of evidence for their efficacy. The transition to precision medicine and early intervention at the pre-ataxic stage are essential for effectively combating neurodegeneration. This review summarizes the latest data on the treatment of SCA, including existing and new treatments, their effectiveness, limitations, and future prospects.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"453-471"},"PeriodicalIF":2.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13390520/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lingual pressure as a physiological indicator for dysphagia in amyotrophic lateral sclerosis and multiple system atrophy. 舌压作为肌萎缩侧索硬化症和多系统萎缩患者吞咽困难的生理指标。

IF 2.8

Neurodegenerative disease management Pub Date : 2026-08-01 Epub Date: 2025-11-06 DOI: 10.1080/17582024.2025.2580876

Jin Magara, Taku Suzuki, Midori Yoshihara, Wakana Onuki, Anna Sasa, Takanori Tsujimura, Makoto Inoue

{"title":"Lingual pressure as a physiological indicator for dysphagia in amyotrophic lateral sclerosis and multiple system atrophy.","authors":"Jin Magara, Taku Suzuki, Midori Yoshihara, Wakana Onuki, Anna Sasa, Takanori Tsujimura, Makoto Inoue","doi":"10.1080/17582024.2025.2580876","DOIUrl":"10.1080/17582024.2025.2580876","url":null,"abstract":"Background: This study aimed to characterize lingual pressure (LP) and clarify its association with dysphagia in patients with amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA).Methods: We examined 52 patients with ALS (Spinal-onset, 39; bulbar-onset, 13) and 36 patients with MSA (MSA-C, 26; MSA-P, 10). LP was measured using a balloon-type instrument during isometric contractions. Maximum LP (MLP) and 80% endurance of LP (ELP; duration above 80% of MLP during 7 seconds) were analyzed against videofluoroscopic findings of dysphagia.Results: Both parameters significantly correlated with food intake scales, especially in ALS. Liquid aspiration was predicted in ALS with 80.8% accuracy (AUC = 0.794, p < 0.001) using MLP cutoff of 20.5 kPa, and in MSA with 75.0% accuracy (AUC = 0.786, p < 0.01) using an ELP cutoff of 1.68 second. Predictive accuracy improved in spinal-onset ALS and MSA-C.Conclusion: LP thus may represent a physiological indicator for dysphagia detection and management.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"391-400"},"PeriodicalIF":2.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13390504/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145452523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Plain language summary: the evoke(+) studies of semaglutide for early Alzheimer's disease. 简明扼要：西马鲁肽治疗早期阿尔茨海默病的研究进展。

IF 2.8

Neurodegenerative disease management Pub Date : 2026-08-01 Epub Date: 2026-05-20 DOI: 10.1080/17582024.2026.2666332

Jeffrey L Cummings, Alireza Atri, Mary Sano, Henrik Zetterberg, Philip Scheltens, Filip K Knop, Peter Johannsen, Christian A Wichmann, Rikke Mortensen Abschneider, Teresa Leon, Jim Taylor, Howard H Feldman

引用次数: 0

Diagnosis and management of frontotemporal dementia: a narrative review. 额颞叶痴呆的诊断和治疗：一个叙述性的回顾。

IF 2.8

Neurodegenerative disease management Pub Date : 2026-08-01 Epub Date: 2026-06-17 DOI: 10.1080/17582024.2026.2687481

Valentina Cenacchi, Tiziana Lombardo, Federica Palacino, Tatiana Cattaruzza, Paolo Manganotti, Alberto Benussi

{"title":"Diagnosis and management of frontotemporal dementia: a narrative review.","authors":"Valentina Cenacchi, Tiziana Lombardo, Federica Palacino, Tatiana Cattaruzza, Paolo Manganotti, Alberto Benussi","doi":"10.1080/17582024.2026.2687481","DOIUrl":"10.1080/17582024.2026.2687481","url":null,"abstract":"Frontotemporal dementia (FTD) is an umbrella term that encompasses a group of clinically heterogeneous neurodegenerative disorders. It is biologically referred to as Frontotemporal lobar degeneration (FTLD) and is characterized by progressive degeneration of frontal and/or temporal lobes. FTD poses substantial diagnostic and therapeutic challenges due to its heterogeneous clinical presentations, limited biomarker specificity, and overlap with other neurodegenerative and psychiatric diseases. This review synthesizes updated knowledge on the clinical phenotypes of FTD, their prognostic elements, and the underlying genetic and molecular mechanisms. Advances in diagnostic strategies are discussed, including structural and functional neuroimaging, fluid biomarkers, and genetic testing, together with emerging digital and AI-assisted tools that may enhance diagnostic precision. Evidence-based management approaches are examined, alongside the role of multidisciplinary care and caregiver support. Promising therapeutic strategies, including gene-targeted interventions, antisense oligonucleotides, progranulin restoration strategies, immunotherapies, and neuromodulation techniques, are discussed considering recent clinical and preclinical developments. Despite the absence of approved disease-modifying therapies, rapid progress in biomarker development, patient stratification, and personalized approaches offers encouraging prospects for more effective interventions across the FTD spectrum. PubMed/MEDLINE was searched for peer-reviewed articles on FTD diagnosis and management; reference lists of key articles were screened to identify additional sources.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"485-510"},"PeriodicalIF":2.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13390543/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148265377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Punding in dementia: an insight into its occurrence, clinical characteristics, treatment, and outcome. 敲打在痴呆：洞察其发生，临床特点，治疗和结果。

IF 2.8

Neurodegenerative disease management Pub Date : 2026-08-01 Epub Date: 2026-02-27 DOI: 10.1080/17582024.2026.2637429

Shailendra Mohan Tripathi, Porimita Chutia, Mohit Kumar Shahi, Samiksha Supranjali, Richa Shukla, Roshni Basu Roy

{"title":"Punding in dementia: an insight into its occurrence, clinical characteristics, treatment, and outcome.","authors":"Shailendra Mohan Tripathi, Porimita Chutia, Mohit Kumar Shahi, Samiksha Supranjali, Richa Shukla, Roshni Basu Roy","doi":"10.1080/17582024.2026.2637429","DOIUrl":"10.1080/17582024.2026.2637429","url":null,"abstract":"Aim: This study investigates punding in dementia, its characteristics, treatment options, and outcomes.Methods: In this retrospective hospital-based study of 55 dementia patients, punding severity, cognition, and neuropsychiatric symptoms assessed using Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale, Hindi Mental Status Examination, and Neuropsychiatric Inventory were collected from baseline to week 8 after treatment. Chi-square and independent t-tests were used to compare groups and repeated measures ANOVA was used to investigate the change in rating scale scores on treatment.Results: The mean age of the patients was 72.8 ± 6.7 years, and 76.4% were of Alzheimer's disease. The frequency of punding in this hospital-based cohort was 61.8%. The mean duration of punding was 4.09 + 2.7 months, and repeated handling of clothes was the prominent characteristic. The patients were treated with low-dose risperidone and SSRI and significant improvement in the severity scores of punding was observed following treatment initiation.Conclusion: Punding is a prevalent behavior in hospitalized patients with dementia. Rapid improvement in punding behavior was observed with combination pharmacotherapy of low dose SSRI and risperidone in our clinical sample. Further multicentric prospective controlled trials are required to establish treatment efficacy of this combination treatment for punding in dementia.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"417-425"},"PeriodicalIF":2.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13390513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147317773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of functional autonomy and neuropsychiatric symptoms in dementia and Mild Cognitive Impairment: a retrospective observational protocol. 评估痴呆和轻度认知障碍患者的功能自主和神经精神症状：一项回顾性观察方案。

IF 2.8

Neurodegenerative disease management Pub Date : 2026-08-01 Epub Date: 2026-05-20 DOI: 10.1080/17582024.2026.2676827

Irene Cappadona, Francesco Corallo, Maria Pagano, Davide Cardile, Lilla Bonanno, Simona Massimino, Rosaria De Luca, Antonella Alagna, Lorena Parisi, Francesco Di Prima, Angela Marra, Rocco Salvatore Calabrò, Anna Anselmo

{"title":"Evaluation of functional autonomy and neuropsychiatric symptoms in dementia and Mild Cognitive Impairment: a retrospective observational protocol.","authors":"Irene Cappadona, Francesco Corallo, Maria Pagano, Davide Cardile, Lilla Bonanno, Simona Massimino, Rosaria De Luca, Antonella Alagna, Lorena Parisi, Francesco Di Prima, Angela Marra, Rocco Salvatore Calabrò, Anna Anselmo","doi":"10.1080/17582024.2026.2676827","DOIUrl":"10.1080/17582024.2026.2676827","url":null,"abstract":"Background: Neurocognitive disorders involve progressive cognitive decline, reduced functional autonomy, and frequent emotional or neuropsychiatric symptoms. Their variable progression highlights the need to identify factors linked to faster deterioration.Aim: This study aims to longitudinally examine functional autonomy, cognitive performance, and neuropsychiatric symptoms in individuals with mild cognitive impairment (MCI) and dementia to support more targeted and personalized interventions.Materials and methods: This retrospective, single-center observational study includes patients who completed three neuropsychological evaluations approximately 12 months apart (T0, T1, T2). The dataset is expected to include at least 151participants . Data include demographic and diagnostic information, cognitive tests (MMSE, MoCA, MODA, FAB, CDT), functional measures (ADL, IADL), and emotional-behavioral scales (BDI, BAI, GDS, HDR-S, HRSA, NPI). Analyses involve descriptive statistics, group comparisons, longitudinal models, regression analyses, and propensity score methods.Results: Dementia patients are expected to show greater functional decline than those with MCI, although some may maintain autonomy. Emotional-behavioral symptoms are anticipated to correlate with accelerated deterioration.Conclusions: This protocol offers a multidimensional framework for characterizing decline in neurocognitive disorders and identifying early predictors of progression, supporting more tailored monitoring and intervention strategies.Clinical trial registration: www.clinicaltrials.gov identifier is NCT07287410.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"443-451"},"PeriodicalIF":2.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13390531/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147974325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0